At a glance
- Originator AstraZeneca
- Class Anti-inflammatories; Antiplatelets
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic nephropathies; Thrombosis
Most Recent Events
- 06 Sep 2000 Discontinued-Preclinical for Thrombosis in United Kingdom (Unknown route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 16 Mar 1999 Discontinued-Preclinical for Diabetic nephropathies in United Kingdom (Unknown route)